Related Articles

• TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
• Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues
• DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Article Page

Hypertension is a major preventable risk factor for atherosclerosis and ischemic heart disease. Although modern and effective antihypertensive drugs are available, most patients remain with a suboptimal blood pressure control. Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals – recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets. In this review, we analyse the latest information available regarding the treatment of hypertension with combination therapy.

Keywords: antihypertensive drugs, cardiovascular disease, combination therapy, hypertension, therapeutic goals.

Citation: Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs in Context 2018; 7: 212531. DOI: 10.7573/dic.212531

Disclosure and potential conflicts of interest: The authors declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/05/dic.212531-COI.pdf

Copyright: Copyright © 2018 Guerrero-García C, Rubio-Guerra AF. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Guerrero-García C, Rubio-Guerra AF. https://doi.org/10.7573/dic.212531. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/combination-therapy-in-the-treatment-of-hypertension

Correspondence: Alberto Francisco Rubio-Guerra, Plan de San Luis S/N Esq Bandera, Col Ticomán, México D.F. C.P. 07330. clinhta@hotmail.com

Provenance: invited; externally peer reviewed.

Submitted: 23 February 2018; Peer review comments to author: 12 March 2018; Revised manuscript received: 7 May 2018; Accepted: 8 May 2018; Publication date: 6 June 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com